New hope for Tough-to-Treat cervical cancer
NCT ID NCT07336147
Summary
This study is testing if adding a new immunotherapy drug, dostarlimab, to the standard treatment of chemotherapy and radiation works better for a rare and aggressive type of cervical cancer. It aims to see if this combination helps patients live longer without their cancer getting worse. The trial is for women aged 20-70 who have not had prior treatment for this specific cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Linkou Branch
RECRUITINGTaoyuan District, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.